Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 4, 2010, Pages 441-444

  Appleman, Maria D ^a   Citron, Diane M ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Staphylococcus aureus; Vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; TREND STUDY;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77649310725     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.11.008     Document Type: Article

References (19)

1. Applebaum P.C. Reduced glycopeptides susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30 (2007) 398-408
2. Clinical and Laboratory Standards Institute (CLSI). Methods for determining bactericidal activity of antimicrobial agents; approved standard, M26-A (1999), CLSI, Wayne, PA
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 18th information supplement (M100-S18) (2008), CLSI, Wayne, PA
4. French G. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J. Antimicrob. Chemother. 58 (2006) 1107-1117
5. Forouzesh A., Moise P.A., et al. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 53 (2009) 483-486
6. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42 (2006) S13-S24
7. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48 (2004) 4665-4672
8. Lodise T.P., Lomaestro B., et al. Larger vancomycin doses (at least 4 grams per day) are associated with increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52 (2008) 1330-1336
9. Musta A.C., Riederer K., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47 (2009) 1640-1644
10. Peterson L.R., and Shanholtzer C.J. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin. Microbiol. Rev. 5 (1992) 420-432
11. Rybak M.J., Lomaestro B.M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49 (2009) 325-327
12. Sader H.S., and Jones R.N. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the daptomycin surveillance program (2007-2008). Diag. Microb. Infect. Dis. 65 (2009) 158-162
13. Sader H.S., Fritsche T.R., et al. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 2330-2336
14. Sader H.S., Jones R.N., et al. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing blood stream infections in nine USA hospitals. J. Antimicrob. Chemother. 64 (2009) 1024-1028
15. Sakoulas G., Moise-Broder P.A., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42 (2004) 2398-2402
16. Soriano A., Marco F., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46 (2008) 193-200
17. Steinkraus G., White R., et al. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60 (2007) 788-794
18. Tenover F.C., and Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44 (2007) 1208-1215
19. Wang G., Hindler J.F., et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44 (2006) 3883-3886